BR112017014433A2 - proteína dnase i modificada, processo para preparar proteína dnase i modificada e composição farmacêutica - Google Patents
proteína dnase i modificada, processo para preparar proteína dnase i modificada e composição farmacêuticaInfo
- Publication number
- BR112017014433A2 BR112017014433A2 BR112017014433-6A BR112017014433A BR112017014433A2 BR 112017014433 A2 BR112017014433 A2 BR 112017014433A2 BR 112017014433 A BR112017014433 A BR 112017014433A BR 112017014433 A2 BR112017014433 A2 BR 112017014433A2
- Authority
- BR
- Brazil
- Prior art keywords
- protein
- modified
- dna
- proteinase
- modified dnase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21001—Deoxyribonuclease I (3.1.21.1)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
proteína dnase i modificada, processo para preparar proteína dnase i modificada e composição farmacêutica, fornece uma proteína dnase i modificada na qual um ou mais aminoácido(s) de uma proteína dnase i é(são) não celularmente modificado(s); a proteína dnase i modificada exibe uma atividade hidrolítica de dna na presença de actina e uma atividade hidrolítica de dna melhorada comparada a uma proteína dnase i não modificada homóloga. processos de preparação da proteína dnase i modificada e usos respectivos, por exemplo, na redução de um teor de dna no escarro e/ou no tratamento de uma doença ou condição associada ao excesso de dna extracelular em um fluido, secreção ou tecido de um indivíduo também são fornecidos.
Applications Claiming Priority (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562099560P | 2015-01-04 | 2015-01-04 | |
US201562099565P | 2015-01-04 | 2015-01-04 | |
US62/099,565 | 2015-01-04 | ||
US62/099,560 | 2015-01-04 | ||
US201562163497P | 2015-05-19 | 2015-05-19 | |
US62/163,497 | 2015-05-19 | ||
US201562169724P | 2015-06-02 | 2015-06-02 | |
US62/169,724 | 2015-06-02 | ||
US201562247856P | 2015-10-29 | 2015-10-29 | |
US62/247,856 | 2015-10-29 | ||
PCT/IL2016/050003 WO2016108244A1 (en) | 2015-01-04 | 2016-01-04 | Modified dnase and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017014433A2 true BR112017014433A2 (pt) | 2018-05-15 |
Family
ID=55442842
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017014433-6A BR112017014433A2 (pt) | 2015-01-04 | 2016-01-04 | proteína dnase i modificada, processo para preparar proteína dnase i modificada e composição farmacêutica |
Country Status (13)
Country | Link |
---|---|
US (2) | US11225648B2 (pt) |
EP (1) | EP3240896A1 (pt) |
CN (1) | CN107406837A (pt) |
AU (1) | AU2016204793B2 (pt) |
BR (1) | BR112017014433A2 (pt) |
CA (1) | CA2970216A1 (pt) |
HK (1) | HK1245822A1 (pt) |
IL (1) | IL253208B2 (pt) |
MX (1) | MX2017008567A (pt) |
NZ (1) | NZ733912A (pt) |
RU (1) | RU2017125957A (pt) |
WO (1) | WO2016108244A1 (pt) |
ZA (1) | ZA201704903B (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016204793B2 (en) * | 2015-01-04 | 2021-12-16 | Protalix Ltd. | Modified DNase and uses thereof |
TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
BR112019009925A2 (pt) | 2016-11-17 | 2019-10-08 | Iovance Biotherapeutics Inc | método para preparar linfócitos infiltrantes de tumor remanescente para terapia de células t adotivas, e, método de tratamento de um câncer . |
JP2021510539A (ja) | 2018-01-16 | 2021-04-30 | シーエルエス セラピューティクス リミテッドCLS Therapeutics Limited | デオキシリボヌクレアーゼ(DNase)活性を有する酵素の肝臓発現による疾患の処置 |
JP7384906B2 (ja) * | 2018-07-09 | 2023-11-21 | ジーアールオー・バイオサイエンシズ・インコーポレイテッド | 非標準アミノ酸含有組成物とその使用 |
WO2020106709A1 (en) * | 2018-11-19 | 2020-05-28 | Gro Biosciences Inc. | Human dnase for lung disease |
US20230416707A1 (en) | 2020-10-07 | 2023-12-28 | Protalix Ltd. | Long-acting dnase |
WO2022178078A1 (en) | 2021-02-19 | 2022-08-25 | Theripion, Inc. | Paraoxonase fusion polypeptides and related compositions and methods |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
DE68929551T2 (de) * | 1988-12-23 | 2008-03-06 | Genentech, Inc., South San Francisco | Menschliche DNase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5469750A (en) | 1991-03-05 | 1995-11-28 | Aradigm Corporation | Method and apparatus for sensing flow in two directions and automatic calibration thereof |
WO1993020949A1 (en) | 1992-04-09 | 1993-10-28 | Omron Corporation | Ultrasonic atomizer, ultrasonic inhalator and method of controlling same |
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
US5694919A (en) | 1993-01-29 | 1997-12-09 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activated dispenser |
US5507277A (en) | 1993-01-29 | 1996-04-16 | Aradigm Corporation | Lockout device for controlled release of drug from patient-activateddispenser |
US5888477A (en) | 1993-01-29 | 1999-03-30 | Aradigm Corporation | Use of monomeric insulin as a means for improving the bioavailability of inhaled insulin |
DE69535787D1 (de) * | 1994-03-04 | 2008-08-28 | Genentech Inc | Verbesserte dnase flüssige lösungen |
US6051256A (en) | 1994-03-07 | 2000-04-18 | Inhale Therapeutic Systems | Dispersible macromolecule compositions and methods for their preparation and use |
US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
US5509404A (en) | 1994-07-11 | 1996-04-23 | Aradigm Corporation | Intrapulmonary drug delivery within therapeutically relevant inspiratory flow/volume values |
US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
US6348343B2 (en) * | 1995-02-24 | 2002-02-19 | Genentech, Inc. | Human DNase I variants |
SK284191B6 (sk) * | 1995-02-24 | 2004-10-05 | Genentech, Inc. | Aktín-rezistentný variant humánnej DNázy I |
US6391607B1 (en) | 1996-06-14 | 2002-05-21 | Genentech, Inc. | Human DNase I hyperactive variants |
GB2316323B (en) | 1996-06-20 | 1999-09-22 | Aid Medic Ltd | Dispensing system |
EP0952821A4 (en) | 1996-12-31 | 2006-07-26 | Nektar Therapeutics | METHODS FOR DRYING AQUEOUS SUSPENSION OF HYDROPHOBIC DRUGS WITH HYDROPHILIC EXCIPIENTS AND COMPOSITIONS PREPARED THEREFROM |
US5855564A (en) | 1997-08-20 | 1999-01-05 | Aradigm Corporation | Aerosol extrusion mechanism |
US6397838B1 (en) | 1998-12-23 | 2002-06-04 | Battelle Pulmonary Therapeutics, Inc. | Pulmonary aerosol delivery device and method |
GB9903433D0 (en) | 1999-02-15 | 1999-04-07 | The Technology Partnership Plc | Droplet generation method and device |
US6962151B1 (en) | 1999-11-05 | 2005-11-08 | Pari GmbH Spezialisten für effektive Inhalation | Inhalation nebulizer |
DE10013093B4 (de) | 2000-03-17 | 2005-12-22 | Inamed Gmbh | Vorrichtung zur kontrollierten Inhalation therapeutischer Aerosole |
EP1249244A1 (en) | 2001-04-13 | 2002-10-16 | Universiteit Gent | Therapeutic compositions for the treatment of a disease modulated by the G-actin / F-actin equilibrium, especially a respiratory tract disease |
DE10123749A1 (de) | 2001-05-16 | 2002-12-12 | Inamed Gmbh | Vorrichtung zum Verabreichen von Aerosolen |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US20030044493A1 (en) | 2001-06-28 | 2003-03-06 | Rettey David C. | Container comprising edible manifold |
US8431123B2 (en) | 2003-07-14 | 2013-04-30 | Cls Therapeutics Limited | Method for treating systemic bacterial, fungal and protozoan infection |
US8388951B2 (en) | 2003-07-14 | 2013-03-05 | Cls Therapeutics Limited | Method for treating systemic DNA mutation disease |
RU2269356C2 (ru) | 2003-07-14 | 2006-02-10 | Дмитрий Дмитриевич Генкин | Способ лечения онкологических заболеваний |
WO2006006963A2 (en) | 2004-04-02 | 2006-01-19 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Aerosol delivery systems and methods |
US8916151B2 (en) | 2005-04-25 | 2014-12-23 | Cls Therapeutics Limited | Method for treating a reduction of fertility |
WO2007131113A2 (en) | 2006-05-03 | 2007-11-15 | Board Of Regents, The University Of Texas System | Modulation of calmodulin- binding transcription activator (camta) as a treatment for cardiac hypertrophy, heart failure, and heart injury |
US20080131497A1 (en) | 2006-09-28 | 2008-06-05 | Perkins Walter R | Formulations of DNase and Methods of Use Thereof |
CN101563134A (zh) | 2006-10-18 | 2009-10-21 | 派利尼斯有限公司 | 用于诊断和治疗男性低生育力的方法和药物组合物 |
PL2095825T3 (pl) | 2006-11-28 | 2011-12-30 | Cls Therapeutics Ltd | Sposób leczenia ludzkich chorób związanych ze zwiększoną zawartością kwasu deoksyrybonukleinowego w przestrzeniach pozakomórkowych i tkankach i preparat leczniczy do przeprowadzenia tego sposobu |
WO2011004476A1 (ja) | 2009-07-09 | 2011-01-13 | パイオニア株式会社 | スピーカ装置 |
EP2809780B1 (en) | 2012-02-01 | 2018-05-02 | Protalix Ltd. | Dnase i polypeptides, polynucleotides encoding same, methods of producing dnase i and uses thereof in therapy |
AU2016204793B2 (en) | 2015-01-04 | 2021-12-16 | Protalix Ltd. | Modified DNase and uses thereof |
-
2016
- 2016-01-04 AU AU2016204793A patent/AU2016204793B2/en active Active
- 2016-01-04 CN CN201680012991.2A patent/CN107406837A/zh active Pending
- 2016-01-04 WO PCT/IL2016/050003 patent/WO2016108244A1/en active Application Filing
- 2016-01-04 US US15/540,264 patent/US11225648B2/en active Active
- 2016-01-04 CA CA2970216A patent/CA2970216A1/en active Pending
- 2016-01-04 NZ NZ733912A patent/NZ733912A/en unknown
- 2016-01-04 IL IL253208A patent/IL253208B2/en unknown
- 2016-01-04 MX MX2017008567A patent/MX2017008567A/es unknown
- 2016-01-04 RU RU2017125957A patent/RU2017125957A/ru not_active Application Discontinuation
- 2016-01-04 EP EP16706685.1A patent/EP3240896A1/en active Pending
- 2016-01-04 BR BR112017014433-6A patent/BR112017014433A2/pt not_active Application Discontinuation
-
2017
- 2017-07-19 ZA ZA2017/04903A patent/ZA201704903B/en unknown
-
2018
- 2018-03-23 HK HK18104094.7A patent/HK1245822A1/zh unknown
-
2021
- 2021-12-20 US US17/555,557 patent/US11814657B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2016204793B2 (en) | 2021-12-16 |
IL253208B (en) | 2022-11-01 |
RU2017125957A (ru) | 2019-02-04 |
WO2016108244A1 (en) | 2016-07-07 |
CA2970216A1 (en) | 2016-07-07 |
MX2017008567A (es) | 2018-04-26 |
CN107406837A (zh) | 2017-11-28 |
US20220106578A1 (en) | 2022-04-07 |
AU2016204793A1 (en) | 2017-08-10 |
NZ733912A (en) | 2023-04-28 |
HK1245822A1 (zh) | 2018-08-31 |
US20180112201A1 (en) | 2018-04-26 |
ZA201704903B (en) | 2023-10-25 |
US11814657B2 (en) | 2023-11-14 |
EP3240896A1 (en) | 2017-11-08 |
IL253208B2 (en) | 2023-03-01 |
IL253208A0 (en) | 2017-08-31 |
US11225648B2 (en) | 2022-01-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017014433A2 (pt) | proteína dnase i modificada, processo para preparar proteína dnase i modificada e composição farmacêutica | |
BR112018003316A2 (pt) | compostos e métodos para entrega transmembrana de moléculas | |
MX2019011215A (es) | Ácidos nucleicos que codifican proteínas asociadas a crispr y usos de los mismos. | |
BR112019001887A2 (pt) | composições e métodos para o tratamento de doença associada a cep290 | |
BR112016016705A8 (pt) | Processo para a purificação de oligossacarídeos neutros de leite humano (hmo), oligossacarídeo de leite humano (hmo) neutro, e uso de um hmo | |
BR112016023559A2 (pt) | mutações de deleção | |
TR201820102T4 (tr) | Fabri hastalığı gen tedavisi. | |
BR112017004349A2 (pt) | terapia com gene de globina para o tratamento de hemoglobinopatias | |
BR112016027871A2 (pt) | composição para melhorar a memória, a função de aprendizado e/ou função cognitiva | |
BR112017016663A2 (pt) | oligômero, conjugado, composição, kit, e, métodos para inibir ou reduzir a expressão de proteína tau em uma célula e para tratar ou prevenir um distúrbio neurológico | |
BR112014007069A2 (pt) | proteínas de fusão para o tratamento de distúrbios metabólicos | |
BR112013026114A2 (pt) | composições nutricionais que incluem ácidos graxos de cadeia ramificada e processos de utilização das mesmas | |
BR112017023391A2 (pt) | ?composição, método para preparar uma composição e métodos para melhorar a hidratação da pele? | |
BR112017013453A2 (pt) | novo peptídeo inibidor de pi3ky para o tratamento de doenças do sistema respiratório | |
BR112016016342A2 (pt) | Polipeptídeo variante que tem atividade de lactase, sequência de ácido nucleico, construto de ácido nucleico, vetor de expressão recombinante, método para produzir uma lactase, método para produzir uma variante de polipeptídeo de lactase, composição, uso de um polipeptídeo variante, processo para a produção de um produto lácteo e produto lácteo | |
BR112017008184A2 (pt) | composições e linhagem | |
BR112019008810A2 (pt) | micrornas modificadas com 5-halouracila e seu uso no tratamento de câncer | |
BR112017012588A2 (pt) | compostos heteroaril-heteroarila bicíclicos de ácido benzoico como agonistas de receptores beta do ácido retinoico (rarbeta) | |
BR112012033714A2 (pt) | polipeptídeo com atividade de acetil xilano esterase e seus usos. | |
BR112016030730A8 (pt) | composto | |
BR112016015678A2 (pt) | Polipeptídeo contendo fragmentos mutantes de ospa, ácido nucleico, vetor, célula hospedeira, processo para sua produção, composição farmacêutica, e seu uso | |
BR112016023688A2 (pt) | célula hospedeira, métodos para produzir um bioconjugado, para tratar ou prevenir uma infecção por pseudomonas em um indivíduo e para induzir uma resposta imune contra pseudomonas em um indivíduo, bioconjugado, composição, uso de um bioconjugado ou uma composição, e, sequência de ácido nucleico isolada | |
BR112019011462A2 (pt) | peptídeo coagonista de gip/glp-1, e, peptídeo para uso no tratamento e/ou profilaxia da doença de alzheimer clínica. | |
BR112016013420A2 (pt) | células eucarióticas e métodos para expressar recombinantemente um produto de interesse | |
BR112019000201A2 (pt) | compostos e seu uso na redução dos níveis de ácido úrico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |